What CJ Bioscience does

CJ Bioscience is a South Korean biotechnology company and subsidiary of CJ Group that develops AI-powered microbiome science solutions spanning drug discovery, biomarker identification, infectious disease diagnostics, and precision nutrition. Founded in 2009 and headquartered in Seoul, the company operates an integrated platform architecture centered on its proprietary Ez-Mx® AI platform, which leverages over 20 years of accumulated gut microbiome analysis data combined with proprietary databases — a 1.2M+ entry Genome Database, a 28,000+ entry Metagenome Database, a 3.8M+ entry Functional Reference Database, and 12,000+ preserved bacterial strains. The company claims the world's largest microbiome drug pipeline, with lead candidates CJRB-201 for inflammatory bowel disease (IBD) and CJRB-101 in multi-country clinical trials for immuno-oncology applications targeting solid tumors including lung and head/neck squamous cell carcinoma.

The company's commercial footprint spans three business lines: (1) B2B SaaS-based microbiome analysis services (EzBioCloud™ and EzBioCloud Pro) serving researchers across 150+ countries, with 67,288 registered users and 3.5M+ cumulative analyses performed; (2) B2B partnerships with pharmaceutical companies for companion diagnostics and drug development; and (3) consumer-facing gut health testing services (Gut Inside, Smile Gut) and a precision nutrition platform (MAC) distributed through medical institutions in South Korea. The recently announced precision nutrition integrated platform combines the patent-pending DIGEST gut simulation system, DIGEST-Flow dynamic monitoring, and machine learning-based response prediction, validated through a 186-participant clinical trial demonstrating reproducible microbiome changes in human subjects. The company also operates TrueBac™ ID, positioned as the world's first genome-based infectious disease diagnostic service.

CJ Bioscience operates as a private subsidiary under CJ CheilJedang's wellness business division, with no venture capital ownership signals identified in available materials. Revenue and detailed financial information are not publicly disclosed. The company maintains active R&D operations including conference participation at KMB 2026 and IHMC 2026, ongoing clinical trials for drug candidates, and a planned H2 2026 commercial launch of a customized MAC precision nutrition solution. The company employs 51-100 staff and is led by founder & CEO Jon Chun.

Name

CJ Bioscience

Legal name

씨제이바이오사이언스 주식회사

Website

https://cjbioscience.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

CJ Bioscience is a South Korean AI-powered microbiome science company developing drug candidates (CJRB-201 for IBD, CJRB-101 for solid tumors), SaaS bioinformatics platforms (EzBioCloud), and precision nutrition solutions serving pharmaceutical companies, research institutions, and consumers globally.

Ownership category

akta.pro rank

Product category

Microbiome Bioinformatics & Therapeutics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

akta.pro secondary industries

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK), Microbiome & Metagenomics Services (HLAGANAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Microbiome therapeutics
• Bioinformatics analysis
• Gut health diagnostics
• Genomic sequencing services
• Precision nutrition platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

CJ Bioscience develops and commercializes AI-powered microbiome science solutions, including the Ez-Mx® analysis platform, the EzBioCloud™ SaaS bioinformatics service, the TrueBac™ ID genome-based infectious disease diagnostic, the MAC precision nutrition integrated platform, and consumer gut microbiome testing services (Gut Inside, Smile Gut). The company also maintains what it describes as the world's largest microbiome drug pipeline, with candidates CJRB-201 (IBD) and CJRB-101 (solid tumors) in multi-country clinical trials, supported by proprietary databases covering 1.2M+ Genome DB entries, 28,000+ Metagenome DB entries, and 3.8M+ Functional Reference DB entries.

Product overview

CJ Bioscience offers a unified platform architecture centered on the Ez-Mx® AI-powered microbiome platform, complemented by multiple integrated products and services. The portfolio includes SaaS-based genomic analysis services (EzBioCloud™, EzBioCloud Pro), genome-based infectious disease diagnostics (TrueBac™ ID), consumer-facing gut health services (Gut Inside, Smile Gut), the precision nutrition MAC platform, and a pipeline of microbiome-based drug candidates (CJRB-101, CJRB-201) targeting oncology and inflammatory bowel disease. The ecosystem is built on proprietary databases including 1.2M+ Genome DB, 28,000+ Metagenome DB, 3.8M+ Functional Reference DB, and 12,000+ bacterial strains, supporting analysis across 150+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Ez-Mx: AI-based precision analysis platform for disease prevention, diagnosis, and treatment across the healthcare spectrum.
• EzBioCloud
• EzBioCloud Pro
• TrueBac ID
• Gut Inside
• MAC
• DIGEST
• DIGEST-Flow
• Smile Gut

Products and services

• Ez-Mx® Platform AI-powered precision analysis platform that supports disease prevention, diagnosis, and treatment workflows, integrating genomic analysis, biomarker discovery, and companion diagnostics to accelerate pharmaceutical drug development. Targeted at pharmaceutical R&D and precision medicine programs.
• EzBioCloud™ SaaS-based bioinformatics analysis service for microbial identification and microbiome genomic analysis, used by researchers worldwide. Powered by CJ Bioscience's proprietary microbial genome database, it is positioned as a global standard bioinformatics service for the microbiome research community.
• TrueBac™ ID Genome-based infectious disease diagnosis service that rapidly identifies unknown pathogens to guide optimal treatment methods. Designed for clinical and research laboratories requiring rapid, accurate infectious disease diagnostics.
• Gut Inside Adult-targeted intestinal microorganism examination service distributed through specialized medical institutions for gut microbiome health assessment. Targeted at South Korean consumers seeking clinically-supervised gut microbiome testing.
• Smile Gut Consumer-focused digital service for personalized gut health management through individual gut microorganism analysis. Targeted at consumers managing gut wellness digitally outside the medical-institution channel.
• MAC (My Alimentary Code) Precision nutrition integrated platform connecting analysis, gut simulation (DIGEST), clinical evidence, and AI-based response prediction for full-cycle verification of nutritional intervention efficacy. Targeted at nutrition, wellness, and consumer health applications, with planned customization as individual MAC solutions.
• CJRB-201 Microbiome-based drug candidate for Inflammatory Bowel Disease (IBD) treatment that colonizes the gut to produce butyrate and active metabolites, connecting to Treg induction and mucosal barrier recovery mechanisms. Targeted at pharmaceutical partners and eventually patients with IBD.
• CJRB-101 Microbiome-based drug candidate targeting solid tumors including lung cancer and head and neck squamous cell carcinoma, advancing through multi-country clinical trials for Immuno-Oncology applications. Targeted at oncology patients and pharmaceutical partners in immuno-oncology.
• NGS Service Next Generation Sequencing-based microbiome genome analysis service using highest-level NGS and bioinformatics technology to provide total bioinformatics solutions in the microbial field. Targeted at research institutions and pharmaceutical clients requiring outsourced sequencing and analysis.
• BI Consulting Service Bioinformatics consulting service providing specialized analysis support for researchers and organizations. Targeted at clients needing custom microbiome study design, data analysis, and bioinformatics interpretation.

Quantifiable outcome

• 3x higher species-level microbial identification accuracy compared to public databases
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• DayTwo: Personalized nutrition platform based on gut microbiome analysis, serving both consumers and B2B (including health plans and providers). Closely comparable on consumer microbiome-based precision nutrition business model.
• Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile and IBD, with a major partnership with Janssen. Comparable on microbiome-defined therapeutics and IBD pipeline overlap.
• MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardized gut microbiome therapies for oncology (GvHD) and IBD. Direct competitor in microbiome-based drug pipeline targeting similar indications.
• Finch Therapeutics: Microbiome therapeutics company developing targeted microbial cocktails for IBD and recurrent C. difficile infection. Direct peer in defined-consortium microbiome drug development.
• Second Genome: Microbiome drug discovery company using proprietary bioinformatics and screening platform to identify microbial targets. Comparable on AI/bioinformatics-driven microbiome drug discovery approach.
• Rebiotix (Ferring Pharmaceuticals): Microbiome therapeutics pioneer (RBX2660 for recurrent C. difficile, now FDA-approved as Rebyota under Ferring). Most advanced microbiome therapeutic peer; comparable pipeline scope and clinical maturity.
• Assembly Biosciences: Clinical-stage biotechnology company with a microbiome-focused drug discovery platform targeting IBD and other inflammatory diseases. Direct comparable in microbiome therapeutic pipeline and bioinformatics platform strategy.
• Seres Therapeutics: US clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD (SER-109) and immuno-oncology. Most direct global peer given overlapping IBD drug development and microbiome therapeutic focus.
• 4D Pharma: Clinical-stage Live Biotherapeutic company with pipeline candidates across oncology, IBD, and respiratory disease. Closely aligned microbiome therapeutics scope and multi-indication strategy.
• Viome Life Sciences: Consumer-facing AI-driven microbiome testing and personalized nutrition company. Direct comparable on Gut Inside/Smile Gut consumer testing and precision nutrition offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/cjbioscience
• LinkedInlinkedin.com/company/cjbioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CJ Bioscience